Elisabeth C. van Turenhout

Elisabeth C. van Turenhout

Auto-generated profile, based on publicly available information

Elisabeth C. van Turenhout

Department of Anaesthesiology, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 January 2020 in Transfusion Medicine
Verified
Journal Article
Open access
PDF file
ETElisabeth C. van Turenhout
Elisabeth C. van Turenhout
SBSebastiaan M. Bossers
Sebastiaan M. Bossers
SLStephan A. Loer
Stephan A. Loer
GGGeorgios F. Giannakopoulos
Georgios F. Giannakopoulos
LSLothar A. Schwarte
Lothar A. Schwarte
PSPatrick Schober
Patrick Schober
Summary: The primary aim of this systematic review is to describe the effects of prehospital transfusion of red blood cells (PHTRBC) on patient outcomes. Damage control resuscitation attempts to prevent death through haemorrhage in trauma patients. In this context, transfusion of red blood cells is increasingly used by emergency medical services (EMS). However, evidence on the effects on outcomes is scarce. PubMed and Web of Science were searched through January 2019; 55 articles were included. No randomised controlled studies were identified. While several observational studies suggest an increased survival after PHTRBC, consistent evidence for beneficial effects of PHTRBC on survival was not found. PHTRBC appears to improve haemodynamic parameters, but there is no evidence that shock on arrival to hospital is averted, nor of an association with trauma induced coagulopathy or with length of stay in hospitals or intensive care units. In conclusion, PHTRBC is increasingly used by EMS, but there is no strong evidence for effects of PHTRBC on mortality. Further research with study designs that allow causal inferences is required for more conclusive evidence. The combination of PHTRBC with plasma, as well as the use of individualised transfusion criteria, may potentially show more benefits and should be thoroughly investigated in the future. The review was registered at Prospero (CRD42018084658).

21 February 2020 in Transfusion Medicine
Verified
Journal Article
Open access
PDF file
ETElisabeth C. van Turenhout
Elisabeth C. van Turenhout
SBSebastiaan M. Bossers
Sebastiaan M. Bossers
SLStephan A. Loer
Stephan A. Loer
GGGeorgios F. Giannakopoulos
Georgios F. Giannakopoulos
LSLothar A. Schwarte
Lothar A. Schwarte
PSPatrick Schober
Patrick Schober
Objectives: The primary aim of this scoping review is to describe the current use of pre‐hospital transfusion of red blood cells (PHTRBC) and to evaluate criteria used to initiate PHTRBC. The effects on patients' outcomes will be reviewed in Part 2.Background: Haemorrhage is a preventable cause of death in trauma patients, and transfusion of red blood cells is increasingly used by Emergency Medical Services (EMS) for damage control resuscitation. However, there are no guidelines and little consensus on when to initiate PHTRBC.Methods: PubMed and Web of Science were searched through January 2019; 71 articles were included.Results: Transfusion triggers vary widely and involve vital signs, clinical signs of poor tissue perfusion, point of care measurements and pre‐hospital ultrasound imaging. In particular, hypotension (most often defined as systolic blood pressure ≤ 90 mmHg), tachycardia (most often defined as heart rate ≥ 120/min), clinical signs of poor perfusion (eg, prolonged capillary refill time or changes in mental status) and injury type (ie, penetrating wounds) are common pre‐hospital transfusion triggers.Conclusions: PHTRBC is increasingly used by Emergency Medical Services, but guidelines on when to initiate transfusion are lacking. We identified the most commonly used transfusion criteria, and these findings may provide the basis for consensus‐based pre‐hospital transfusion protocols.

10 July 2014 in International Journal of Endocrinology
Verified
Journal Article
Open access
PDF file
CLCarmilla M. M. Licht
Carmilla M. M. Licht
LTLise C. van Turenhout
Lise C. van Turenhout
JDJan Berend Deijen
Jan Berend Deijen
LKLando L. J. Koppes
Lando L. J. Koppes
WMWillem van Mechelen
Willem van Mechelen
MDMadeleine L. Drent
Madeleine L. Drent
Several studies have demonstrated an association between polymorphisms in the insulin-like growth factor-1 (IGF-1) gene and IGF-1 serum levels. IGF-1 levels have been associated with cognitive functioning in older persons and growth hormone deficient patients. The present study investigates whether IGF-1 polymorphisms, IGF-1 levels, and cognition are interconnected in healthy adults. Data of 277 participants (mean age: 42.4 years) of the Amsterdam Growth and Health Longitudinal Study on IGF-1 promoter polymorphisms, IGF-1 serum level, spatial working memory (SWM), paired associate learning (PAL), and IQ tests were analyzed. (M)ANOVAs were applied to confirm the associations between IGF-1 polymorphisms and IGF-1 levels and between IGF-1 levels and cognition. Three groups were distinguished based on specific IGF-1 polymorphism alleles: a homozygote 192 bp/192 bp genotype, a heterozygote 192 bp/x genotype, and a noncarrier x/x genotype. Although different IGF-1 levels were found for the three genotypes, performance on all cognitive tasks and IQ measures was similar. Despite the associations between IGF-1 polymorphisms and IGF-1 levels, no association was found between cognition and IGF-1 levels. It seems that IGF-1 does not play a role in the cognitive performance of healthy middle-aged adults. Possible, IGF-1 fulfills a more developmental and protective role in cognition which becomes apparent during childhood, old-age, or disease.

3 May 2011 in The Open Neuroendocrinology Journal
Verified
Journal Article
Open access
PDF file
ETE.C. van Turenhout
E.C. van Turenhout
JDJ.B. Deijen
J.B. Deijen
LKL.L.J. Koppes
L.L.J. Koppes
WMW. van Mechelen
W. van Mechelen
JTJ.W.R. Twisk
J.W.R. Twisk
MDM.L. Drent
M.L. Drent
Age- and Sex-Related Interactions between Insulin-Like Growth Factor-I Promoter Polymorphisms and IGF-I Levels